Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Alexandria T. Phan MD

Alexandria T. Phan MD profile photo picture

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

View Curriculum Vitae

Publications (57)

  • Neuroendocrine Tumors: a Relevant Clinical Update. (Rizen EN, Phan AT) Curr Oncol Rep 2022 Jun;24(6):703-714 PMID: 35254612 SCOPUS ID: 2-s2.0-85125805464 03/08/2022       10 Citations
  • Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. (Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P, CLARINET Investigators) Endocrine 2021 Feb;71(2):502-513 PMID: 33052555 PMCID: PMC7881960 SCOPUS ID: 2-s2.0-85092563674 10/15/2020       38 Citations
  • Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. (Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME, CLARINET Study Group) Anticancer Drugs 2020 Mar;31(3):216-222 PMID: 31977567 PMCID: PMC7028287 SCOPUS ID: 2-s2.0-85079344984 01/25/2020       5 Citations
  • Molecular pathways and targeted therapy in cholangiocarcinoma. (Dabney RS, Khalife M, Shahid K, Phan AT) Clin Adv Hematol Oncol 2019 Nov;17(11):630-637 PMID: 31851165 SCOPUS ID: 2-s2.0-85074712470 12/19/2019       15 Citations
  • Immunotherapy and targeted therapy-the new roadmap in cancer treatment. (Shahid K, Khalife M, Dabney R, Phan AT) Ann Transl Med 2019 Oct;7(20):595 PMID: 31807576 PMCID: PMC6861781 12/07/2019    
  • Stereotactic body radiation therapy and immunotherapy. (Khalife M, Shahid K, Dabney RS, Phan AT) Clin Adv Hematol Oncol 2019 Sep;17(9):518-523 PMID: 31549973 SCOPUS ID: 2-s2.0-85072566084 09/25/2019       3 Citations
  • Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. (Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM) Int J Cancer 2020 Apr 01;146(7):1836-1840 PMID: 31241762 SCOPUS ID: 2-s2.0-85068533287 06/27/2019       13 Citations
  • Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. (Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI, CLARINET Study Investigators) Oncologist 2019 Apr;24(4):463-474 PMID: 30355775 PMCID: PMC6459235 SCOPUS ID: 2-s2.0-85055425505 10/26/2018       13 Citations
  • BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS. (Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, Lowenthal SP, Vinik AI) Endocr Pract 2018 Aug 07 PMID: 30084687 SCOPUS ID: 2-s2.0-85058153549 08/08/2018       8 Citations
  • Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition. (Yu Y, Kong R, Cao H, Yin Z, Liu J, Nan X, Phan AT, Ding T, Zhao H, Wong STC) Oncotarget 2018 Jun 15;9(46):27958-27973 PMID: 29963254 PMCID: PMC6021345 SCOPUS ID: 2-s2.0-85048607629 07/03/2018       11 Citations
  • Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. (Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT) Clinicoecon Outcomes Res 2017;9:495-503 PMID: 28860831 PMCID: PMC5566387 SCOPUS ID: 2-s2.0-85029482731 09/02/2017       8 Citations
  • Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Discussion. (Iyer R, Phan AT, Boudreaux JP) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):18-19 PMID: 28654026 SCOPUS ID: 2-s2.0-85039049564 06/28/2017    
  • Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors. (Phan AT) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):10-14 PMID: 28654024 SCOPUS ID: 2-s2.0-85039066695 06/28/2017       1 Citation
  • Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium. (Iyer R, Phan AT, Boudreaux JP) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):1-24 PMID: 28654022 SCOPUS ID: 2-s2.0-85039039165 06/28/2017       4 Citations
  • Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. (Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO) Clin Gastroenterol Hepatol 2017 Nov;15(11):1791-1799 PMID: 28579181 PMCID: PMC5901750 SCOPUS ID: 2-s2.0-85040458288 06/06/2017       78 Citations
  • Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. (Nan X, Qin Q, Gentille C, Ensor J, Leveque C, Pingali SR, Phan AT, Rice L, Iyer S) Leuk Lymphoma 2017 Sep;58(9):1-11 PMID: 28140714 SCOPUS ID: 2-s2.0-85011310993 02/01/2017       21 Citations
  • Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences. (Ryan P, Phan AT, Adelman DT, Iwasaki M) Clin J Oncol Nurs 2016 Dec 01;20(6):E139-E146 PMID: 27857269 SCOPUS ID: 2-s2.0-84996536289 11/20/2016       6 Citations
  • The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. (Phan AT, Dave B) Cancer Med 2016 Oct;5(10):2953-2964 PMID: 27539383 PMCID: PMC5083749 SCOPUS ID: 2-s2.0-84992445175 10/30/2016       13 Citations
  • Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. (Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT) J Gastrointest Cancer 2016 Dec;47(4):366-374 PMID: 27619395 PMCID: PMC5138269 SCOPUS ID: 2-s2.0-84987638423 09/14/2016       21 Citations
  • Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. (Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P, CLARINET Investigators) Endocr Relat Cancer 2016 Mar;23(3):191-9 PMID: 26743120 PMCID: PMC4740728 SCOPUS ID: 2-s2.0-84963958033 01/09/2016       199 Citations
  • Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. (Crumley SM, Pepper KL, Phan AT, Olsen RJ, Schwartz MR, Portier BP) Arch Pathol Lab Med 2016 Jun;140(6):529-35 PMID: 26536055 SCOPUS ID: 2-s2.0-84971422004 11/05/2015       16 Citations
  • New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. (Phan AT, Kunz PL, Reidy-Lagunes DL) Clin Adv Hematol Oncol 2015 May;13(5 Suppl 5):1-18; quiz 1 p following 18 PMID: 26430956 SCOPUS ID: 2-s2.0-84979094370 10/03/2015    
  • Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. (Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH) Lancet Oncol 2015 Jun;16(6):695-703 PMID: 25956795 PMCID: PMC4800487 SCOPUS ID: 2-s2.0-84930504063 05/10/2015       105 Citations
  • Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. (Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D) Gastroenterology 2015 Jul;149(1):119-29 PMID: 25836985 PMCID: PMC4778392 SCOPUS ID: 2-s2.0-84931295870 04/04/2015       88 Citations
  • Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. (Phan AT) Clin Adv Hematol Oncol 2014 Dec;12(12 Suppl 19):3-5 PMID: 25768101 SCOPUS ID: 2-s2.0-84941045857 03/15/2015       2 Citations
  • Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. (Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS) Pancreas 2015 Mar;44(2):190-7 PMID: 25426617 PMCID: PMC6063309 SCOPUS ID: 2-s2.0-84925873579 11/27/2014       55 Citations
  • A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. (Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM) BMC Cancer 2014 Aug 02;14:561 PMID: 25086465 PMCID: PMC4125701 SCOPUS ID: 2-s2.0-84924804904 08/05/2014       12 Citations
  • Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators) N Engl J Med 2014 Jul 17;371(3):224-33 PMID: 25014687 SCOPUS ID: 2-s2.0-84904253184 07/12/2014       967 Citations
  • Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. (Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL Jr, Macapinlac HA, Chuang HH) Eur J Nucl Med Mol Imaging 2014 Nov;41(11):2066-73 PMID: 24990404 SCOPUS ID: 2-s2.0-84939884040 07/06/2014       35 Citations
  • Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. (Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT, Zhao H, Scott JE, Yeh LA, Wong ST) Clin Cancer Res 2014 Jul 01;20(13):3521-30 PMID: 24780296 PMCID: PMC4079752 SCOPUS ID: 2-s2.0-84903837906 05/02/2014       71 Citations
  • Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. (Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E) J Clin Oncol 2013 Sep 01;31(25):3076-82 PMID: 23897970 SCOPUS ID: 2-s2.0-84886003527 07/31/2013       253 Citations
  • Consensus guidelines for the management and treatment of neuroendocrine tumors. (Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC, North American Neuroendocrine Tumor Society) Pancreas 2013 May;42(4):557-77 PMID: 23591432 PMCID: PMC4304762 SCOPUS ID: 2-s2.0-84876840005 04/18/2013       465 Citations
  • Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. (Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F) Cancer Res 2013 Mar 01;73(5):1449-53 PMID: 23436795 SCOPUS ID: 2-s2.0-84874862127 02/26/2013       68 Citations
  • Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. (Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R) Br J Cancer 2013 Mar 05;108(4):826-30 PMID: 23412108 PMCID: PMC3590681 SCOPUS ID: 2-s2.0-84875230967 02/16/2013       96 Citations
  • The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. (Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL) Cancer Res 2012 Nov 15;72(22):5683-91 PMID: 22986737 SCOPUS ID: 2-s2.0-84869209181 09/19/2012       44 Citations
  • The role of taxanes in the management of gastroesphageal cancer. (Jimenez P, Pathak A, Phan AT) J Gastrointest Oncol 2011 Dec;2(4):240-9 PMID: 22811858 PMCID: PMC3397631 07/20/2012    
  • Clinical burden of illness in patients with neuroendocrine tumors. (Hess GP, Chen CC, Liu Z, Yao JC, Phan AT, Hill JW) Pancreas 2012 Oct;41(7):1058-62 PMID: 22513292 SCOPUS ID: 2-s2.0-84865863959 04/20/2012       10 Citations
  • Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective. (Phan AT) Cancer Treat Rev 2013 Feb;39(1):3-9 PMID: 22459199 SCOPUS ID: 2-s2.0-84869079653 03/31/2012       6 Citations
  • PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. (Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J) Clin Cancer Res 2012 Mar 15;18(6):1777-89 PMID: 22422409 PMCID: PMC3307149 SCOPUS ID: 2-s2.0-84863258395 03/17/2012       187 Citations
  • Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. (Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC) Pancreas 2012 Apr;41(3):461-6 PMID: 22422138 SCOPUS ID: 2-s2.0-84859060426 03/17/2012       144 Citations
  • New strategies for advanced neuroendocrine tumors in the era of targeted therapy. (Dong M, Phan AT, Yao JC) Clin Cancer Res 2012 Apr 01;18(7):1830-6 PMID: 22338018 SCOPUS ID: 2-s2.0-84859417274 02/18/2012       44 Citations
  • Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. (Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE) J Clin Endocrinol Metab 2011 Dec;96(12):3741-9 PMID: 21994954 SCOPUS ID: 2-s2.0-83155168540 10/14/2011       176 Citations
  • The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. (Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK, North American Neuroendocrine Tumor Society (NANETS)) Pancreas 2010 Aug;39(6):799-800 PMID: 20664477 PMCID: PMC3100733 SCOPUS ID: 2-s2.0-77955198120 07/29/2010       268 Citations
  • NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). (Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ, North American Neuroendocrine Tumor Society (NANETS)) Pancreas 2010 Aug;39(6):784-98 PMID: 20664476 SCOPUS ID: 2-s2.0-77955216385 07/29/2010       150 Citations
  • Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. (Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG) Cancer 2010 Apr 01;116(7):1656-63 PMID: 20143431 SCOPUS ID: 2-s2.0-77950244862 02/10/2010       15 Citations
  • Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. (Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE) Ann Surg Oncol 2010 Jan;17(1):263-70 PMID: 19851811 SCOPUS ID: 2-s2.0-74649087201 10/24/2009       134 Citations
  • Neuroendocrine tumors: novel approaches in the age of targeted therapy. (Phan AT, Yao JC) Oncology (Williston Park) 2008 Dec;22(14):1617-23; discussion 1623-4, 1629 PMID: 19198220 SCOPUS ID: 2-s2.0-59349087915 02/10/2009       12 Citations
  • Treatment options for metastatic neuroendocrine tumors. (Phan AT, Yao JC, Evans DB) Surgery 2008 Dec;144(6):895-8 PMID: 19040994 SCOPUS ID: 2-s2.0-56449127225 12/02/2008       5 Citations
  • Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. (Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F) J Clin Oncol 2008 Sep 10;26(26):4311-8 PMID: 18779618 PMCID: PMC2653122 SCOPUS ID: 2-s2.0-52049125970 09/10/2008       549 Citations
  • Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. (Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S) Int J Radiat Oncol Biol Phys 2008 May 01;71(1):167-72 PMID: 18406886 SCOPUS ID: 2-s2.0-41849144160 04/15/2008       15 Citations
  • Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. (Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE) Surgery 2007 Dec;142(6):867-75; discussion 867-75 PMID: 18063070 SCOPUS ID: 2-s2.0-36649005347 12/08/2007       77 Citations
  • Clinical benefit of palliative radiation therapy in advanced gastric cancer. (Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S) Acta Oncol 2008;47(3):421-7 PMID: 17899453 SCOPUS ID: 2-s2.0-40949086457 09/28/2007       82 Citations
  • Adrenal cortical carcinoma--review of current knowledge and treatment practices. (Phan AT) Hematol Oncol Clin North Am 2007 Jun;21(3):489-507; viii-ix PMID: 17548036 SCOPUS ID: 2-s2.0-34249811195 06/06/2007       37 Citations
  • Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. (Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA) Cancer 2007 Jan 01;109(1):33-40 PMID: 17133415 SCOPUS ID: 2-s2.0-33846271497 11/30/2006       54 Citations
  • Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. (Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D) J Clin Oncol 2006 Feb 01;24(4):663-7 PMID: 16446338 SCOPUS ID: 2-s2.0-33644833992 02/01/2006       93 Citations
  • Gastric carcinoma. (Phan AT, Ajani JA) Curr Oncol Rep 2004 May;6(3):192-8 PMID: 15066230 SCOPUS ID: 2-s2.0-3042719211 04/07/2004       9 Citations
  • Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. (Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH) Cancer 2001 Jul 15;92(2):406-13 PMID: 11466696 SCOPUS ID: 2-s2.0-0035878068 07/24/2001       249 Citations
    • Last update: 04/19/2024